8-K: Elevance Health Reports Mixed Q4 2024 Results, Sets 2025 Outlook

Elevance Health reported a 6% increase in Q4 operating revenue to $45.0 billion, but experienced a decrease in net income and provided a 2025 outlook with projected EPS growth.

Summary

• Elevance Health's Q4 2024 operating revenue reached $45.0 billion, a 6% increase year-over-year, while full-year 2024 revenue was $175.2 billion, up 3%.
• The company's Q4 diluted EPS was $1.81, and adjusted diluted EPS was $3.84, while full-year diluted EPS was $25.68 and adjusted diluted EPS was $33.04.
• Elevance Health projects a full-year 2025 GAAP diluted EPS in the range of $30.40 to $31.10 and adjusted diluted EPS between $34.15 and $34.85.
• The quarterly dividend was increased by 5% to $1.71 per share.
• The benefit expense ratio increased to 92.4% in Q4 and 88.5% for the full year, driven by higher Medicaid medical costs.
• Medical membership decreased by 1.1 million year-over-year to 45.7 million, primarily due to Medicaid attrition.
• Carelon's operating revenue increased by 19% in Q4 and 12% for the full year, driven by growth in risk-based capabilities and acquisitions.
• The company repurchased 4.5 million shares of its common stock for $1.8 billion in Q4 and has $9.3 billion remaining in its share repurchase authorization.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth offset by declining profits and increased costs. The future outlook is positive but not overwhelmingly so, leading to a neutral sentiment.

Positives

• Operating revenue increased by 6% in Q4 and 3% for the full year.
• Carelon segment showed strong revenue growth, with a 19% increase in Q4 and 12% for the full year.
• The company increased its quarterly dividend by 5%.
• Elevance Health repurchased a significant amount of its own stock in Q4.
• The company projects growth in adjusted diluted EPS for 2025.

Negatives

• Net income decreased by 50.3% in Q4 and 0.1% for the full year.
• The benefit expense ratio increased significantly in both Q4 and the full year.
• Medical membership decreased by 2% year-over-year, primarily due to Medicaid attrition.
• Operating gain in the Health Benefits segment decreased significantly in Q4.

Risks

• Increased healthcare costs, particularly in Medicaid, are impacting profitability.
• Membership attrition in the Medicaid business is a concern.
• The company faces risks related to healthcare regulations and cyber security.
• There are risks associated with mergers, acquisitions, and strategic alliances.
• The company's substantial debt and interest rate increases could impact financing costs.

Future Outlook

Elevance Health projects a full-year 2025 GAAP diluted EPS in the range of $30.40 to $31.10 and adjusted diluted EPS between $34.15 and $34.85. The company anticipates high single to low double digit growth in total operating revenue and mid-teens growth in CarelonRx revenue.

Management Comments

• Gail K. Boudreaux, President and CEO, stated that the company is committed to elevating whole health and advancing health beyond healthcare.
• Management believes the fourth quarter results demonstrate tangible progress in improving operations.
• The company aims to simplify the healthcare experience, deepen the impact of Carelon, and deploy innovative care models to achieve sustainable growth.

Industry Context

The healthcare industry is facing a dynamic environment with increasing costs and changing regulations. Elevance Health's results reflect these challenges, particularly in the Medicaid sector. The company's focus on Carelon and innovative care models aligns with industry trends towards integrated healthcare solutions.

Comparison to Industry Standards

• UnitedHealth Group (UNH), a major competitor, reported a full year 2023 adjusted EPS of $25.12, while Elevance Health reported $33.04 for 2024, indicating a stronger performance in earnings per share.
• Humana (HUM) reported a benefit expense ratio of 87.9% for the full year 2023, while Elevance Health reported 88.5% for 2024, suggesting a slightly higher cost of care for Elevance Health.
• CVS Health (CVS) reported a full year 2023 revenue of $357.8 billion, while Elevance Health reported $175.2 billion for 2024, indicating a smaller scale of operations compared to CVS.
• Elevance Health's focus on Carelon is similar to other large health insurers expanding into healthcare services, such as UnitedHealth Group's Optum division, indicating a trend towards integrated healthcare solutions.

Stakeholder Impact

• Shareholders will see an increased dividend but may be concerned about the decrease in net income.
• Employees may be impacted by the company's cost management efforts.
• Customers may benefit from the company's focus on simplifying the healthcare experience.
• Care providers may see changes as the company deploys innovative care models.

Next Steps

• Management will host a conference call and webcast to discuss the results and outlook.
• The company will continue to focus on simplifying the healthcare experience and growing Carelon.
• Elevance Health will continue to deploy innovative care models to achieve sustainable growth.

Key Dates

Keywords

Elevance Health, Healthcare, Health Insurance, Financial Results, Earnings, EPS, Revenue, Carelon, Medicaid, Medicare, Dividends, Share Repurchase